A PE/VC firm based in China makes early-growth stage investments in several sectors including Healthcare. The firm typically invests USD 5-10 million per company. The firm typically invests in companies located in China but is also interested in companies abroad that have a China angle. For example, companies that plan to set up a JV in China, etc. The firm has no set number of investments it plans to make but could potentially invest in 3-4 healthcare companies in the next 12 months. The firm is actively seeking new investment opportunities.

In Healthcare, the firm seeks to invest in therapeutics, diagnostics, medical equipment/devices, services, and HCIT. The firm is generally opportunistic in terms of subsectors. However, the firm is particularly interested in implantable devices, biomesh, IVD, gene sequencing, and vaccines. For indications, the firm is interested in large markets in China; stated interest includes (but not limited to) orthopedics, oncology, diabetes and obesity, viral diseases, and hepatitis B & C. In terms of stage of development, the firm will consider early-late stages for Chinese companies. For foreign companies, the firm seeks products that already have regulatory approval in their respective market. However, the firm is open to engage with companies with products that are 1-2 years from market approval.

The firm invests in companies in China as well as companies located abroad. However, companies abroad must have a China angle. For example, plans to set up a JV. The firm generally seeks board of directors representation.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A newly established venture capital firm is actively seeking early-stage investment opportunities in life sciences and healthcare sectors. The firm is focused on emerging companies in pre-seed / seed rounds and will participate in Series A at the maximum. Currently, the firm is focused on USA-based companies, but can dedicate up to 20% of their fund to invest outside of the USA.

The firm invests in 4 main focus areas: (1) biotech, which includes biomarkers, liquid biopsies, cell therapy, smart packaging, drug delivery, next generation sequencing, omics; (2) digital health, which includes wearables, diagnostics, services, AI-enabled approaches, management, fitness, digital therapy; (3) medtech, which includes smart devices, smart lens, breath biopsy, 3D printing, in vitro diagnostics, surgical robotics, laser therapy; (4) health edtech, which includes personalized learning, med. professional development, immersive learnings (e.g., VR), wellness. The firm plans to expand their investment capabilities in medtech, as they have recently made great investments in this space. The firm is indication agnostic, and is open to all opportunities including oncology, cardiovascular, infectious, metabolic, neurological, and rare/orphan diseases.

The firm seeks to work with companies backed by a management team with deep domain expertise and technologies that are backed by solid IP. The firm prefers to act as a follow-on, but will seek to lead more investment rounds in the future.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in Canada is making seed and venture investments with its latest fund, and usually seeks to be the first institutional capital in a company. Equity investments are the preferred capital structure; however convertible notes may be employed for seed investments. Initial investments may be as small as $1M (seed-stage companies) with up to $15M allocated over the life of the investment. The firm prefers to lead financing rounds of Canadian companies and co-lead investments based in the United States.

The firm is focused on investments in therapeutics, medtech and diagnostics. The firm is agnostic in terms of subsector and indication and invests in early pre-clinical up unto Phase III therapeutic assets with the caveat being that the capital needs of the company fall within the fund’s criteria for investment size. As for devices and diagnostics stage of development, the firm invests in products in development and in clinical settings given the aforementioned capital constraints for therapeutics. For medtech, the firm has a preference for 510(k) regulatory pathways but will also evaluate devices with a PMA pathway.

The firm has no strict criteria for management teams and will work with novice entrepreneurs, however those management teams with experience are favored. The firm looks to originate 2/3 of its investments in Canada and the rest in the United States, and typically seeks a board seat along with investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A firm with multiple offices in Western Europe has over €1 billion in total assets under management. The firm typically invests €1-5 million in early-stage opportunities or up to €10 million in growth-stage opportunities. The firm is currently focused on companies based in Europe.

Within the life science sector, the firm is currently focused on medical technology, diagnostics, life science tools and platforms, and digital health across Europe. The firm is open to opportunities in any indication area and at any phase of development.

The firm is open to investing in companies at early stages with a proof-of-concept, clinically relevant data and/or strong IP positions.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A global healthcare and life science company drives value in private and public companies through operational and strategic direction as well as patient capital. The firm is headquartered in Western Europe and has an additional office in the USA. Given its structure and source of capital, the firm can acquire interests in early and late stage ventures without restriction on the location of opportunities. As a public company, the firm is a source of permanent capital. Average initial stakes range from $5M – $15M in the form of equity, with additional capital reserved for follow-on investments, The firm prefers to have a Board position in order to actively support the companies in which it invests.

The firm is focused on areas of unmet medical need, strongly favoring breakthrough and cutting-edge technologies over iterative or symptomatic treatments. The firm has particular interests in oncology (especially immuno-oncology), cardiovascular, metabolic, neuroscience indications, anti-infectives, gene therapy, and orphan diseases, as well as other therapeutic areas. The firm invests across the life cycle of development, from company formation through to companies with marketed products.

The firm is open to working with a variety of companies and entrepreneurs, but prefers management teams who have prior experience in the specific stage of development (clinical development, commercial strategy, etc.) and indication/area of their current venture. The firm also looks for startups companies with a strong BOD, SAB and support network (legal, back office, KOLs, etc.), though these are not prerequisites.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An investment firm with offices in USA, Western Europe, and India, is actively seeking investment and partnership opportunities with therapeutics and medical device companies across the globe. In addition, the firm is interested in nutraceuticals and cosmeceuticals. Typical size of initial investment is around $5M, though the firm is capable of investing up to $10M and this is largely dependent on a case-by-case. The firm is capable of funding up to ~40% of the required amount for late stage clinical trials. The firm is also interested in-licensing partnerships and seek licensing and marketing rights on opportunities in which the firm can add significant value.

Within therapeutics and medical devices, the firm is generally sector and indication agnostic. The firm is focused on later-stage opportunities with a low risk profile, usually companies in Phase IIb and beyond. However, the firm is very keen to speaking with earlier stage opportunities that demonstrate strong clinical data and high potential to enter the global market and building a long-term relationship with these groups. In terms of medical devices, the firm will invest in near market ready products. The firm generally does not invest in diagnostics or digital health.

The firm seeks to invest in companies with experienced management teams with domain expertise, strong clinical data, and a clear exit strategy. The firm has an extensive professional network including fellow investors, high net worth individuals, clinical trial/regulatory affairs partners, etc. The firm takes a very active role in supporting their portfolio companies and provides mentorship and support on regulatory issues, market access, and effective clinical development strategies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A private wealth investment firm invests globally in medically related early-stage companies. Initial size of investment largely varies depending on the deal’s stage of development and other involved investors.

The firm invests in medtech and digital health companies. The firm is generally opportunistic and will consider any promising technologies that address unmet medical need. The firm has looked at AI companies, digital health/software companies implementable in medical practices, etc. In terms of stage of development, the firm is open to investing as early as pre-prototype, given that the company has properly researched the idea behind their technology.

The firm has no specific company or management team requirements. While the firm generally co-invests alongside a syndicate, the firm has led a financing before and is open to acting as the lead investor if the firm determines that they could add significant value.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.